Von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in individuals with non-small-cell lung Brilliant Black BN Enterovirus cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589?597. four. Freemantle SJ, Spinella MJ, Dmitrovsky E: Retinoids in cancer therapy and chemoprevention: guarantee meets resistance. Oncogene 2003, 22:7305?315. five. Nowak D, Stewart D, Koeffler HP: Differentiation therapy of leukemia: 3 decades of development. Blood 2009, 113:3655?665. 6. Hormi-Carver K, Feagins LA, Spechler SJ, Souza RF: All trans-retinoic acid induces apoptosis by way of p38 and caspase pathways in metaplastic Azumolene Biological Activity Barrett’s cells. Am J Physiol Gastrointest Liver Physiol 2007, 292:G18 27. 7. Leelawat K, Ohuchida K, Mizumoto K, Mahidol C, Tanaka M: All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion via up-regulation of c-met in pancreatic cancer cells. Cancer Lett 2005, 224:303?10. eight. Tang XH, Gudas LJ: Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011, 6:345?64. 9. Pozzi S, Rossetti S, Bistulfi G, Sacchi N: RAR-mediated epigenetic handle from the cytochrome P450 Cyp26a1 in embryocarcinoma cells. Oncogene 2006, 25:1400?407. ten. Xu XC: Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 2007, 253:14?4. 11. Masia S, Alvarez S, de Lera AR, Barettino D: Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol Endocrinol 2007, 21:2391?402. 12. Brognard J, Clark AS, Ni Y, Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986?997. 13. Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511?526. 14. Guo Y, Du J, Kwiatkowski DJ: Molecular dissection of AKT activation in lung cancer cell lines. Mol Cancer Res 2013, 11:282?93. 15. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988?004. 16. Garcia-Regalado A, Guzman-Hernandez ML, Ramirez-Rangel I, Robles-Molina E, Balla T, Vazquez-Prado J, Reyes-Cruz G: G protein-coupled receptorpromoted trafficking of Gbeta1gamma2 leads to AKT activation at endosomes through a mechanism mediated by Gbeta1gamma2-Rab11a interaction. Mol Biol Cell 2008, 19:4188?200. 17. Song G, Ouyang G, Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005, 9:59?1. 18. Hers I, Vincent EE, Tavare JM: Akt signalling in health and illness. Cell Signal 2011, 23:1515?527. 19. Fritz H, Kennedy D, Fergusson D, Fernandes R, Doucette S, Cooley K, Seely A, Sagar S, Wong R, Seely D: Vitamin A and retinoid derivatives for lung cancer: a systematic assessment and meta analysis. PLoS One 2011, six:e21107. 20. Geradts J, Chen JY, Russell EK, Yankaskas JR, Nieves L, Minna JD: Human lung cancer cell lines exhibit resistance to retinoic acid therapy. Cell Growth Differ 1993, four:799?09. 21. Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E: A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 2005, 97:1645?651. 22. Somenzi G, Sala G, Rossetti S, Ren M, G.
